Novavax Inc (NVAX) — closed signal from April 28, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 27, 2026.
Predicted vs. what happened
NVAX price · publication thesis → realized outcomesplit-adjusted
$7.40 – $8.20Entry zone — fair-value band
$8.04Published — price the day we called it
$9.48Target — the price the thesis aimed for
$11.61Peak — highest point inside the window, not a realized return
$7.49Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 8 days.
Peak price
$11.61
peak on May 27, 2026 — not a realized returnPeak gain
+44.4%
peak, from the publication priceWindow close
$7.49
end-of-window price, context onlyDays to target
8
Window
April 28, 2026 – July 27, 2026
The thesis — published April 28, 2026
Predicted growth
+18%
over the measurement windowTarget price
$9.48
the price the thesis aimed forEntry zone
$7.40 – $8.20
the fair-value band we waited forPrice at publication
$8.04
published April 28, 2026Confidence
64%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novavax is a high-risk biotech pick. A recent analyst note pushing the stock higher on governance news gave it a short-term lift, and the company has enough cash to withstand pressure. Vaccine work is promising, but earnings can swing widely and heavy short positions can make the share price jumpier, so confidence is intentionally modest.
Primary drivers
- Analyst target lift highlights possible governance improvements
- Cash on hand helps the company ride out biotech ups and downs
- Vaccine technology keeps future opportunities open
- High short interest and uneven results can make the stock volatile
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.